No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DGX240816C145000
- 2.35
- +1.15+95.83%
15min DelayClose Jul 24 16:00 ET
2.35High1.30Low
1.45Open1.20Pre Close10 Volume1.34K Open Interest145.00Strike Price1.76KTurnover19.10%IV2.39%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry2.35Extrinsic Value100Contract SizeAmericanOptions Type0.4746Delta0.0575Gamma58.15Leverage Ratio-0.0696Theta0.0418Rho27.59Eff Leverage0.1444Vega
Intraday
- 5D
- Daily
News
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $154
Quest Diagnostics Analyst Ratings
Baird Adjusts Price Target on Quest Diagnostics to $154 From $153
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $150
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $144 to $154
Comments
$Quest Diagnostics(DGX.US$ PathAI + Invigorate + stable finance + qualified management team + decent PE.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
4
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Read more